Clinical Trial Update: An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis [Phase 2]

View source ↗

Summary

This document reports on an open-label extension study of XTMAB-16 for pulmonary sarcoidosis. The trial is in Phase 2 and currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Sarcoidosis

Drugs mentioned

• XTMAB-16

Snippet

Sponsor: Xentria, Inc. | Conditions: Pulmonary Sarcoidosis | Phase 2 | Status: ENROLLING_BY_INVITATION